ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)
|
|
- CAS-Nr.
- 850649-61-5
- Englisch Name:
- ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)
- Synonyma:
- Alogliptin;Trajenta;Alogliptin (SYR-322);ALOGLIPTINA;Axagliptin hydrate;ogL;Agelieting;ALOGLIPTINE;Alogliptin,98%;Unii-jhc049lo86
- CBNumber:
- CB91011068
- Summenformel:
- C18H21N5O2
- Molgewicht:
- 339.39
- MOL-Datei:
- 850649-61-5.mol
|
ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA) Eigenschaften
- Schmelzpunkt:
- 127 - 129°C
- Siedepunkt:
- 519.2±60.0 °C(Predicted)
- Dichte
- 1.342
- Flammpunkt:
- 267.8℃
- storage temp.
- Refrigerator
- L?slichkeit
- Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- pka
- 9.89±0.20(Predicted)
- Farbe
- White to Off-White
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Bildanzeige (GHS) |
|
Alarmwort |
Warnung |
Gefahrenhinweise |
Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
|
|
Sicherheit |
P261 |
Einatmen von Staub vermeiden. |
P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA) Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Alogliptin is a dipeptidyl-peptidase IV (DPP-4) inhibitor that was
approved in Japan in 2010 for treatment of type 2 diabetes, a disease in
which insulin resistance and β-cell dysfunction lead to hyperglycemia.
As islet function is lost, the severity of insulin resistance
increases. The introduction of DPP-4 inhibitors has brought a novel
class of insulinotropic agents for the treatment options available to type
2 diabetic patients. The therapeutic potential of glucagon-like peptide 1
(GLP-1), an incretin peptide, for the treatment of type 2 diabetes was
realized in the 1990s. The insulinotropic effects of GLP-1 depend closely
on glucose concentrations providing the possibility of glucose normalization
without the risk of hypoglycemia. GLP-1 has other non-insulinotropic
physiological actions that are advantageous. It suppresses glucagon
secretion from a cells and slows gastric emptying, which contributes to
satiety and to a slower passage and reabsorption of carbohydrates. GLP-1
also contributes to satiety via a central mechanism as a neurotransmitter
with effects on the hypothalamus.
Chemische Eigenschaften
White Solid
Verwenden
Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4).
Antidiabetic agent.
Definition
ChEBI: A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of t
pe 2 diabetes.
ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA) Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA) Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 268)Lieferanten
850649-61-5()Verwandte Suche:
- Alogliptin(free base)
- Benzonitrile, 2-[[6-[(3R)-3-aMino-1-piperidinyl]-3,4-dihydro-3-Methyl-2,4-dioxo-1(2H)-pyriMidinyl]Methyl]-
- (R)-2-[6-(3-aMino-piperidin-1-yl)-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl]-benzonitrile
- Alogliptin Benzoate API
- Alogliptin
2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile
- ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)
- Unii-jhc049lo86
- 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile
- ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)###850649-61-5
- Trelagliptin-11
- Alogliptin Intermediate
- ALOGLIPTIN(ALOGLIPTINE
- Trelagliptin Impurity T
- (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitri
- Alogliptin, 99%, effective and selective DPP-4 inhibitor
- Alogliptin,98%
- Trelagliptin Impurity 2(Alogliptin)
- ogL
- Troxagliptin impurities141
- Troxagliptin impuritiesT
- AlogliptinQ: What is
Alogliptin Q: What is the CAS Number of
Alogliptin Q: What is the storage condition of
Alogliptin Q: What are the applications of
Alogliptin
- Alogliptin 13C6
- Alogliptin (SYR-322)
- Axagliptin hydrate
- Trajenta
- Alogliptin
- ALOGLIPTINA
- ALOGLIPTINE
- Alogliptin Base
- Trelagllptin Impurity 2
- Agelieting
- 850649-61-5
- Inhibitor
- Intermediates & Fine Chemicals
- Pharmaceuticals
- intermediat
- Inhibitors
- Amines
- Aromatics
- Chiral Reagents
- Heterocycles